Compass Pathways Shares Topline 52-week Results (Part C) From Its Phase 3 COMP005 Trial Of Comp360 For Treatment-Resistant Depression, Showing Additional Benefit Extending Durability Out To 1 Year

뉴스 본문을 불러오고 있어요.

Compass Pathways Shares Topline 52-week Results (Part C) From Its Phase 3 COMP005 Trial Of Comp360 For Treatment-Resistant Depression, Showing Additional Benefit Extending Durability Out To 1 Year | 웨이프 WAPE

Compass Pathways Shares Topline 52-week Results (Part C) From Its Phase 3 COMP005 Trial Of Comp360 For Treatment-Resistant Depression, Showing Additional Benefit Extending Durability Out To 1 Year

기사 요약

관련 종목

댓글 —